259 related articles for article (PubMed ID: 31002319)
1. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
[TBL] [Abstract][Full Text] [Related]
2. Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Everts-Graber J; Bonel H; Lehmann D; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
Osteoporos Int; 2023 Nov; 34(11):1961-1973. PubMed ID: 37493978
[TBL] [Abstract][Full Text] [Related]
3. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
4. Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women.
Hsiao FY; Huang WF; Chen YM; Wen YW; Kao YH; Chen LK; Tsai YW
Clin Ther; 2011 Nov; 33(11):1659-67. PubMed ID: 22018450
[TBL] [Abstract][Full Text] [Related]
5. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.
Abrahamsen B; Eiken P; Eastell R
J Clin Endocrinol Metab; 2010 Dec; 95(12):5258-65. PubMed ID: 20843943
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of Denosumab vs alendronate among postmenopausal women with osteoporosis.
Curtis JR; Arora T; Liu Y; Lin TC; Spangler L; Brunetti VC; Stad RK; McDermott M; Bradbury BD; Kim M
J Bone Miner Res; 2024 May; ():. PubMed ID: 38753892
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
Lin TC; Yang CY; Yang YH; Lin SJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
Lindsay R; Watts NB; Lange JL; Delmas PD; Silverman SL
Osteoporos Int; 2013 Aug; 24(8):2345-52. PubMed ID: 23612793
[TBL] [Abstract][Full Text] [Related]
9. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.
McCloskey EV; Johansson H; Oden A; Austin M; Siris E; Wang A; Lewiecki EM; Lorenc R; Libanati C; Kanis JA
J Bone Miner Res; 2012 Jul; 27(7):1480-6. PubMed ID: 22431426
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
Abelson A; Ringe JD; Gold DT; Lange JL; Thomas T
Osteoporos Int; 2010 Jun; 21(6):1021-9. PubMed ID: 19722103
[TBL] [Abstract][Full Text] [Related]
11. [Incidence of hip fractures due to osteoporosis in relation to the prescription of drugs for their prevention and treatment in Galicia, Spain].
Guerra-García MM; Rodríguez-Fernández JB; Puga-Sarmiento E; Charle-Crespo MÁ; Gomes-Carvalho CS; Prejigueiro-Santás A
Aten Primaria; 2011 Feb; 43(2):82-8. PubMed ID: 20554353
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
13. Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT).
Nakamura T; Matsumoto T; Sugimoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Shiraki M; Fukunaga M
J Clin Endocrinol Metab; 2014 Jul; 99(7):2599-607. PubMed ID: 24646104
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
Lin TC; Lee CH; Yang CY; Yang YH; Lin SJ
J Clin Endocrinol Metab; 2014 May; 99(5):1599-607. PubMed ID: 24606074
[TBL] [Abstract][Full Text] [Related]
15. Hip fractures in users of first- vs. second-generation bisphosphonates.
Mamdani M; Kopp A; Hawker G
Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
[TBL] [Abstract][Full Text] [Related]
16. Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
Ström O; Jönsson B; Kanis JA
Osteoporos Int; 2013 Apr; 24(4):1491-502. PubMed ID: 23224141
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study.
Lai EC; Lin TC; Lange JL; Chen L; Wong ICK; Sing CW; Cheung CL; Shao SC; Yang YK
Osteoporos Int; 2022 May; 33(5):1155-1164. PubMed ID: 35032187
[TBL] [Abstract][Full Text] [Related]
18. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
19. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study.
Abrahamsen B; Rubin KH; Eiken PA; Eastell R
Osteoporos Int; 2013 Jan; 24(1):321-8. PubMed ID: 23070480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
